Email Alert | RSS    帮助

中国防痨杂志 ›› 2020, Vol. 42 ›› Issue (8): 799-806.doi: 10.3969/j.issn.1000-6621.2020.08.005

• 论著 • 上一篇    下一篇

重组结核杆菌融合蛋白(EC)的稳定性与有效性研究

杨蕾*, 韦芬, 张凯, 仇晶晶, 汪莹莹, 都伟欣, 卢锦标, 陶立峰, 蒲江()   

  1. 102629 北京,中国食品药品检定研究院结核病疫苗和过敏原产品室 中国医学科学院生物技术产品检定方法及其标准化重点实验室(杨蕾、都伟欣、卢锦标);安徽智飞龙科马生物制药有限公司(韦芬、张凯、仇晶晶、汪莹莹、陶立峰、蒲江)
  • 收稿日期:2020-06-16 出版日期:2020-08-10 发布日期:2020-08-10
  • 通信作者: 蒲江 E-mail:pujiang@zhifeishengwu.com
  • 基金资助:
    “十二五”国家科技重大专项(2014ZX10003002-004);“十二五”国家科技重大专项(2015ZX09108-004);“十三五”国家科技重大专项(2017ZX10201301-001-003);“十三五”国家科技重大专项(2018ZX10103001-001-008)

Stability and efficacy study of recombinant Mycobacterium tuberculosis fusion protein (EC)

YANG Lei*, WEI Fen, ZHANG Kai, QIU Jing-jing, WANG Ying-ying, DU Wei-xin, LU Jin-biao, TAO Li-feng, PU Jiang()   

  1. *Division of Tuberculosis Vaccine and Allergen, National Institutes for Food and Drug Control, Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Beijing 102629, China
  • Received:2020-06-16 Online:2020-08-10 Published:2020-08-10
  • Contact: PU Jiang E-mail:pujiang@zhifeishengwu.com

摘要:

目的 考察重组结核杆菌融合蛋白(EC)[该制品名称是国家药典委员会确定的药品中文通用名称,“EC”为重组融合蛋白“结核分枝杆菌早期分泌性抗原靶6(ESAT-6)和培养滤液蛋白10(CFP-10)”](以下简称“EC”)原液的储存稳定性、成品储存及使用的稳定性与有效性。方法 (1)原液储存稳定性研究:将3批次EC原液储存于-70℃,观察0~36个月,保存0、3、6、9、12、18、24、36个月时取样进行致敏效应试验、鉴别试验、效价检测,以及等电点、分子量、蛋白质含量、纯度(电泳法)等检测,其中致敏效应试验用豚鼠分为试验组(注射EC原液)与对照组(注射稳定剂),观察注射后动物反应,两组动物反应应无差异;鉴别试验为卡介苗致敏后豚鼠分别皮内注射EC原液和结核菌素纯蛋白衍生物(TB-PPD),观察测量豚鼠皮肤试验检测结果,EC原液皮肤试验应呈阴性反应(硬结或红晕平均直径<5mm),而TB-PPD皮肤试验应呈阳性反应(硬结平均直径≥5mm);效价检测为结核分枝杆菌活菌致敏后6只豚鼠分别皮内注射3个稀释度的EC原液及参考品,观察测量豚鼠皮肤试验检测结果,不同稀释度的EC原液与参考品皮肤试验局部反应的硬结或红晕平均直径总和的比值(以下简称“平均直径总和比值”)应为1.0±0.2;等电点应为3.5~5.3,分子量应为(23±2.0)kDa(1kDa的相对分子质量为1000),蛋白质含量应不低于450.0μg/ml,纯度(电泳法)应不低于95.0%。(2)EC成品储存稳定性研究:成品分别储存于37℃和2~8℃,分别观察0~28d和0~36个月,37℃保存0、7、14、21、28d时、2~8℃保存0、3、6、9、12、18、24、36个月时取样进行鉴别试验、效价检测,以及pH值、苯酚含量等检测,其中鉴别试验方法及检测结果判定如“EC原液”。效价检测为结核分枝杆菌活菌致敏后4只豚鼠分别皮内注射EC成品及参考品,观察测量方法及平均直径总和比值判定如“EC原液”,pH值应为6.8~7.4,苯酚含量应不高于3.0g/L。(3)EC成品使用稳定性研究:成品开启后分别放置于温度(25±2)℃、湿度(60±5)%和温度(40±2)℃、湿度(75±5)%两种条件考察使用过程的稳定性,观察时间为0~50min,分别于0、10、20、30、40、50min取样进行鉴别试验、效价检测,以及pH值、渗透压摩尔浓度等检测,试验方法和检测结果判定如“EC成品”,其中渗透压摩尔浓度应为(280.0±68.0)mOsmol/kg。依据定期取样检测结果是否符合EC质量标准来判断产品稳定性,并为制定EC原液、成品有效期和成品使用时的有效时间提供依据。结果 (1)EC原液-70℃观察0~36个月,在各研究时间点,致敏效应试验均表现为试验组与对照组动物反应无差异;鉴别试验结果为EC原液皮肤试验呈阴性,而TB-PPD皮肤试验呈阳性;效价检测结果为不同稀释度的EC原液与参考品皮肤试验的平均直径总和比值为0.9~1.1;等电点为3.7~5.2;分子量为(23.2~24.2)kDa;蛋白质含量为(501.6~616.7)μg/ml,纯度(电泳法)均为100.0%。(2)EC成品稳定性研究:在各研究时间点,鉴别试验结果为EC成品皮肤试验呈阴性,而TB-PPD皮肤试验呈阳性;效价检测结果显示EC成品与参考品皮肤试验的平均直径总和比值为0.9~1.0; pH值为7.1~7.4、苯酚含量为(2.6~2.9)g/L。(3)EC成品使用稳定性研究结果:在各研究时间点,鉴别试验结果均为EC成品皮肤试验呈阴性,而TB-PPD皮肤试验呈阳性;效价检测结果显示EC成品与参考品皮肤试验的平均直径总和比值均为1.0;pH值为7.1~7.2;渗透压摩尔浓度为(302.4~307.4)mOsmol/kg。结论 EC原液-70℃储存36个月质量稳定;成品37℃储存28d、2~8℃储存36个月质量稳定;成品在开启后50min内使用,质量稳定。

关键词: 重组结核杆菌融合蛋白(EC), 药物稳定性, 有效性研究, 药物评价

Abstract:

Objective To investigate the stability of the bulk storage, finished products storage; in-use stability; and efficacy of recombinant Mycobacterium tuberculosis fusion protein(EC)(Chinese generic name of the drug determined by the National Pharmacopoeia Committee, EC stands for recombinant fusion protein 6-kDa (Relative molecular mass of 1 kDa is 1000) early secreted antigenic target protein (ESAT-6) and the 10-kDa culture filtrate protein (CFP-10))(Hereinafter referred to as “EC”). Methods (1) Bulk storage stability study:3 batches of bulk was placed at -70℃ and observed for 0-36 months, samples were taken in the 0, 3, 6, 9, 12, 18, 24, 36 months for sensitization effect test, identification test, titer test and tests of isoelectric point, molecular weight, protein content, purity (Electrophoresis), etc. In the sensitization effect test, guinea pigs were divided into experimental group (Injection of EC bulk) and control group (Injection of stabilizer), and the animal reaction after injection was observed, where there should be no difference between the two groups. In identification test, BCG sensitized guinea pigs were intradermally injected with EC and tuberculin pure protein derivative(TB-PPD) respectively. The skin test results of guinea pigs were observed and measured. The skin test results of EC should be negative (The average diameter of induration or redness <5 mm), while the skin test results of TB-PPD should be positive (The average diameter of induration ≥5 mm). In titer tests, 6 MTB sensitized guinea pigs, each was injected with 3 EC injections in different dilutions and 3 control injections, observe and measure the test results of guinea pig skin tests, the ratios of the sum of the average diameter of induration or redness of the local reaction to EC bulk injections in different dilutions and that to control injections, should be 1.0±0.2. The isoelectric points should be 3.5-5.3; the molecular weights should be (23±2.0) kDa; the protein contents should be not less than 450.0μg/ml, and the purities (electrophoresis method) should not be less than 95.0%. (2) Final products storage stability study: The final products were stored at 37℃ and 2-8℃ for observed 0-28 days and 0-36 months, respectively. On day 0, 7, 14, 21, 28 at 37℃ and month 0, 3, 6, 9, 12, 18, 24, 36 at 2-8℃, samples were taken for identification test, titer test and pH value, phenol content, etc. For the identification test, test method and result determination see ‘EC bulk’. For titer test, 4 guinea pigs, each was injected with EC final products and control injection respectively, the measurement methods, and the ratios of the sum of the average diameter determination see ‘EC bulk’, pH values should be 6.8-7.4, phenol contents should not be higher than 3.0g/L. (3) Final products in-use stability study: After opening, the final products were placed at two conditions: (25±2)℃, (60±5) % humidity, and (40±2℃), (75±5) % humidity, observe for 50min, to investigate the in use stability, samples were taken at 0, 10,20,30,40,50min, for identification test, titer test and pH value, osmotic pressure molar concentration, test methods and result determination see ‘EC final products’, osmotic pressure molar concentrations should be (280.0±68.0) mOsmol/kg. The stability of the products will be judged according to whether the regular sampling test results meet EC quality standards, it will provide basis for the determination of the validity period of EC bulk and final products, and the in-use effective period of EC final products. Results (1) For EC bulk stored at -70℃, observed for 0-36 months: At each time point, the sensitization effect tests showed no difference between the experimental group and the control group. The identification test results were negative for EC bulk and positive for TB-PPD; for titer test, the ratios of the sum of the average diameter of induration or redness of EC bulk and control injections were 0.9-1.1. The isoelectric points were 3.7-5.2. The molecular weights were (23.2-24.2) kDa. The protein contents were (501.6-616.7)μg/ml, and the purities (electrophoresis method) was 100.0%. (2) For EC final products stability study: At each time point, the identification test results were negative for EC bulk and positive for TB-PPD. For titer test, the ratios of the sum of the average diameter of induration or redness of EC final products and control injections were 0.9-1.0. pH values were 7.1-7.4 and phenol contents were (2.6-2.9) g/L. (3) For final products in-use stability study: At each time point, the identification test results were negative for EC bulk and positive for TB-PPD. For titer test, the ratios of the sum of the average diameter of induration or redness of EC final products and control injections were all 1.0. pH values were 7.1-7.2. Osmotic pressure molar concentrations were (302.4-307.4)mOsmol/kg. Conclusion EC bulk is quality stable to be stored for 36 months at -70℃. EC final products are quality stable to be stored for 28 d at 37℃ and 36 months at 2-8℃. After opening, the final products are quality stable for 50min.

Key words: Recombinant Mycobacterium tuberculosis fusion protein(EC), Drug stability, Efficacy study, Drug evaluation